Opendata, web and dolomites

FACTs

Fast Acting Virus Control Strategies for Production Animal Diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FACTs project word cloud

Explore the words cloud of the FACTs project. It provides you a very rough idea of what is the project "FACTs" about.

markets    billions    clinical    disease    contamination    ing    animals    plan    leaders    infected    feedlot    amounts    prevent    variability    stage    minimize    sales    antigenic    arrival    business    cattle    separated    immune    virovet    house    mortality    alone    producing    introducing    initially    150    signed    maximize    market    industry    difficult    diarrhoea    investment    predicted    regulatory    auction    decreased    continuous    euros    supportive    disruptive    virus    utero    costing    opinion    rapid    vaccines    treatment    massive    infection    conduct    secondary    refinement    shedding    efficiency    beef    finalized    bovine    sheet    infect    introduction    facts    expressed    form    host    shed    administered    brazil    company    belgian    successful    kols    investors    sign    labour    unable    launched    conventional    exposed    assist    contracts    time    biotech    endemic    globally    million    vaccination    peak    persistently    return    bvd    consult    added    pi    susceptibility    detect    viral    herd    calves    standard    reduce    until    feed    drug    trl    inadequate   

Project "FACTs" data sheet

The following table provides information about the project.

Coordinator
ARATANA THERAPEUTICS NV 

Organization address
address: AMBACHTENLAAN 1
city: HEVERLEE
postcode: 3001
website: www.okapi-sciences.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Project website http://www.virovet.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ARATANA THERAPEUTICS NV BE (HEVERLEE) coordinator 50˙000.00

Map

 Project objective

The objective of the FACTs project is to sign a term sheet with investors for ViroVet, an emerging Belgian biotech company, aimed at developing and introducing a disruptive treatment for bovine viral diarrhoea (BVD) in beef cattle. BVD is a globally endemic disease of cattle costing the industry billions of Euros every year in the form of increased mortality, decreased feed efficiency and increased susceptibility to secondary disease. Conventional BVD vaccines are unable to fully control the disease due to antigenic variability of the virus and inadequate host immune response to vaccination. BVD virus can infect calves in utero leading to persistently infected (PI) animals that are difficult to detect but that shed massive amounts of virus, resulting in continuous contamination of the herd. The product will initially be launched in the EU and US, with other large beef-producing markets, such as Brazil, also considered. It will be administered to cattle upon arrival at the feedlot or auction house, which is a time of high susceptibility to infection. The drug will prevent exposed animals from developing clinical disease and will reduce viral shedding by PI animals until they are identified and separated from the herd. The drug will be added to standard processing procedures to minimize labour time and cost. The BVD project is in TRL-6 stage and is predicted to reach market in 6-8 years’ time with peak sales of €150 million in the EU and US alone. Key opinion leaders (KOLs) are supportive of the product and a number of investors have expressed their interest. In Phase I, ViroVet will conduct market research and consult with KOLs in Europe and in other major beef markets to ensure successful introduction of the product. A comparative analysis of regulatory requirements will assist in the refinement of the business plan that will minimize time to market and maximize rapid return on investment. Contracts with investors will be finalized and a term sheet will be signed.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FACTS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FACTS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

N-IF (2017)

The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies

Read More